- Home
- ADPT vs IHS Comparison
ADPT vs IHS Comparison
Compare ADPT & IHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- IHS
- Stock Information
- Founded
- ADPT 2009
- IHS 2001
- Country
- ADPT United States
- IHS United Kingdom
- Employees
- ADPT N/A
- IHS N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- IHS Telecommunications Equipment
- Sector
- ADPT Health Care
- IHS Telecommunications
- Exchange
- ADPT Nasdaq
- IHS Nasdaq
- Market Cap
- ADPT 2.0B
- IHS 2.3B
- IPO Year
- ADPT 2019
- IHS 2021
- Fundamental
- Price
- ADPT $14.40
- IHS $6.78
- Analyst Decision
- ADPT Strong Buy
- IHS Strong Buy
- Analyst Count
- ADPT 9
- IHS 7
- Target Price
- ADPT $13.22
- IHS $10.18
- AVG Volume (30 Days)
- ADPT 2.1M
- IHS 483.9K
- Earning Date
- ADPT 11-06-2025
- IHS 11-11-2025
- Dividend Yield
- ADPT N/A
- IHS N/A
- EPS Growth
- ADPT N/A
- IHS N/A
- EPS
- ADPT N/A
- IHS 0.33
- Revenue
- ADPT $205,216,000.00
- IHS $1,731,025,000.00
- Revenue This Year
- ADPT $32.76
- IHS $1.97
- Revenue Next Year
- ADPT $15.81
- IHS $5.50
- P/E Ratio
- ADPT N/A
- IHS $20.44
- Revenue Growth
- ADPT 21.60
- IHS N/A
- 52 Week Low
- ADPT $4.27
- IHS $2.44
- 52 Week High
- ADPT $15.26
- IHS $7.66
- Technical
- Relative Strength Index (RSI)
- ADPT 60.53
- IHS 47.71
- Support Level
- ADPT $14.04
- IHS $6.66
- Resistance Level
- ADPT $15.26
- IHS $6.85
- Average True Range (ATR)
- ADPT 0.73
- IHS 0.19
- MACD
- ADPT 0.05
- IHS -0.03
- Stochastic Oscillator
- ADPT 69.09
- IHS 43.75
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.